Gynecologic Oncology Practice Questions

Q: What condition is the EMACO regimen primarily used to treat?

Choriocarcinoma. ***Choriocarcinoma*** - The **EMACO** regimen (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine) is a highly effective chemotherapy protocol for treating **gestational trophoblastic neoplasia**, particularly **choriocarcinoma**. - This regimen is chosen for its efficacy in targeting rapidly dividing trophoblastic cells and its ability to achieve **high cure rates** even in metastatic disease. *Cervical cancer* - Treatment for cervical cancer often involves surgery, radiation therapy, and chemotherapy regimens like cisplatin-based combinations, not typically **EMACO**. - EMACO is specifically designed for proliferative trophoblastic diseases, which have different cellular characteristics than **cervical carcinomas**. *Endometrial cancer* - Endometrial cancer is primarily managed with surgery, sometimes followed by radiation or chemotherapy with agents such as carboplatin and paclitaxel, distinct from the **EMACO protocol**. - The pathology and biology of **endometrial adenocarcinoma** differ significantly from choriocarcinoma, requiring different treatment approaches. *Ovarian cancer* - The standard treatment for ovarian cancer usually involves surgery followed by chemotherapy, frequently using drugs like carboplatin and paclitaxel. - **Ovarian neoplasms** are diverse, but the EMACO regimen is not a standard first-line or common chemotherapy option for most types of ovarian cancer.

Q: What is the recommended treatment for stage III B cervical cancer?

Combined chemoradiation (chemotherapy + radiotherapy). ***Combined chemoradiation (chemotherapy + radiotherapy)*** - For **Stage IIB-IVA cervical cancer**, combined chemoradiation is the standard of care, offering superior outcomes compared to either modality alone. - The combination of **cisplatin-based chemotherapy** and **external beam radiation therapy (EBRT)**, often followed by **brachytherapy**, improves local control and survival rates. *Radical hysterectomy (Wertheim's operation)* - **Radical hysterectomy** is generally reserved for **early-stage cervical cancer (IA2-IIA)** that is surgically resectable. - In Stage IIIB disease, the tumor has spread to the **pelvic sidewall** and/or involves the **lower third of the vagina**, making surgical resection highly unlikely to achieve negative margins and posing a high risk of complications. *Radiotherapy (external beam)* - While **radiotherapy** is a crucial component of treatment for locally advanced cervical cancer, using it as a standalone treatment for Stage IIIB is **less effective** than combined chemoradiation. - Concurrent chemotherapy, particularly with **cisplatin**, sensitizes tumor cells to radiation, thereby **enhancing the efficacy of radiotherapy** and improving survival. *Chemotherapy (intravenous)* - **Chemotherapy alone** is generally insufficient for curing locally advanced cervical cancer due to its limited ability to eradicate macroscopic disease. - It is primarily used here as a **radiosensitizer** to augment the effects of radiation therapy, not as a primary monotherapy.

Q: What is the recommended approach for adjuvant treatment in endometrial carcinoma stage IA, grade I?

No adjuvant treatment. ***No adjuvant treatment*** - **Stage IA, Grade I endometrial carcinoma** is considered a **low-risk disease** with an excellent prognosis following surgery alone. - The risk of recurrence is minimal, making **adjuvant therapy unnecessary** and not beneficial for improving survival outcomes. *Radiotherapy* - Adjuvant radiotherapy is typically reserved for **higher-risk endometrial cancers** (e.g., higher grade, deeper myometrial invasion, lymphovascular space invasion) to reduce locoregional recurrence. - For **stage IA, grade I disease**, the potential benefits of radiotherapy do not outweigh the risks of its side effects. *Chemotherapy* - Chemotherapy is generally used for **advanced or high-risk endometrial cancers**, often those with systemic spread or specific histological subtypes (e.g., serous, clear cell). - It is **not indicated** for early-stage, low-grade disease like stage IA, grade I, as it offers no survival benefit in this setting. *Chemotherapy plus radiotherapy* - This combined modality approach is reserved for **high-risk endometrial cancers**, often those with extensive disease or aggressive features, to target both local and systemic disease. - For **stage IA, grade I endometrial cancer**, this combination would be **overtreatment**, exposing the patient to significant toxicity without additional benefit.

Q: In a patient with choriocarcinoma and jaundice, what is the most appropriate treatment option?

Multi-agent combination chemotherapy. ***Multi-agent combination chemotherapy*** - The presence of **jaundice** in a patient with choriocarcinoma indicates **liver metastasis**, classifying this as **high-risk gestational trophoblastic neoplasia** (WHO risk score ≥7). - High-risk metastatic choriocarcinoma requires **multi-agent combination chemotherapy** such as the **EMA-CO regimen** (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine/Oncovin). - This approach achieves **cure rates of 80-90%** even in advanced metastatic disease with organ involvement. - Surgical intervention is generally **not indicated** for established metastatic choriocarcinoma. *Methotrexate* - Methotrexate is a **single-agent chemotherapy** regimen used only for **low-risk gestational trophoblastic neoplasia** (WHO score <7). - It is **insufficient for high-risk disease** with liver metastasis and would lead to treatment failure and disease progression. *Actinomycin D* - Actinomycin D is another **single-agent chemotherapy** option for **low-risk disease only**. - Like methotrexate, it would be **inadequate as monotherapy** for high-risk metastatic choriocarcinoma presenting with jaundice. *Suction evacuation* - **Suction evacuation** is a procedure for removing molar tissue during or after evacuation of a **hydatidiform mole**. - It is **not appropriate for established choriocarcinoma**, especially metastatic disease, where the diagnosis is made by elevated β-hCG and histology/imaging. - In metastatic choriocarcinoma, **chemotherapy is the definitive treatment**, and surgical intervention could cause complications like perforation or hemorrhage.

Q: In which of the following conditions is therapeutic conization MOST specifically indicated as the standard treatment approach?

Microinvasive carcinoma of the cervix. ***Microinvasive carcinoma of the cervix*** - **Therapeutic conization** is the definitive standard treatment for **microinvasive carcinoma (Stage IA1)**, serving as both diagnostic and potentially curative management. - It allows precise assessment of depth of invasion, lymphovascular space invasion (LVSI), and margin status while preserving fertility. - This is the **most specifically indicated** condition where conization is the standard therapeutic approach, not just diagnostic. *Severe Cervical Intraepithelial Neoplasia (CIN III) requiring excision* - CIN III can be treated with multiple excisional methods including **LEEP, cold knife conization, or laser ablation**. - Conization is one option among several, not the most specifically indicated single approach. *Benign cervical metaplasia* - **Benign cervical metaplasia** is a normal physiological process of squamous epithelium replacing columnar epithelium. - No treatment is required; surgical intervention would be inappropriate and cause unnecessary harm. *High-grade cervical dysplasia with unsatisfactory colposcopy* - Unsatisfactory colposcopy (transformation zone not fully visible) with high-grade dysplasia requires diagnostic excision, typically via conization. - However, in this context, conization is performed primarily for **diagnostic purposes** (to visualize and assess the full extent of disease and rule out invasion) rather than as the specific **therapeutic standard**. - Unlike microinvasive carcinoma where conization is the established therapeutic approach, here it addresses a diagnostic limitation.

Q: Which of the following is the least likely site for metastasis in cases of vulvar cancer?

Paraaortic nodes. ***Paraaortic nodes*** - **Paraaortic nodes** are typically involved only in advanced or very widespread metastatic disease of the vulva, usually after involvement of more proximal lymphatic basins or direct tumor extension. - The **lymphatic drainage** of the vulva primarily follows a defined pathway, making direct spread to paraaortic nodes less common than to other regional nodes. *Urethra* - The **urethra** can be a site of local invasion or direct extension from a vulvar tumor, especially if the tumor is located near the clitoris or anterior vulva. - Direct spread to adjacent structures is a common route of tumor progression in many cancers, including vulvar cancer. *Deep inguinal nodes* - The **deep inguinal lymph nodes** are a common secondary site of metastasis, receiving lymphatic drainage from superficial inguinal nodes and sometimes directly from vulvar tissue. - Involvement of these nodes indicates more advanced regional spread than superficial inguinal node involvement alone, but still follows the primary lymphatic pathways. *Superficial inguinal nodes* - The **superficial inguinal lymph nodes** are the **primary drainage site** for the vulva and are the most common site for initial lymphatic metastasis. - Their involvement is a critical factor in staging vulvar cancer and guiding treatment decisions.

Q: Which ovarian tumour can present with menorrhagia ?

Granulosa cell tumour. ***Granulosa cell tumour*** - This tumour secretes **estrogen**, which can lead to **endometrial hyperplasia** and subsequently cause **menorrhagia** (heavy or prolonged menstrual bleeding). - Its hormonal activity is a key differentiator from other ovarian tumours that typically do not cause such menstrual irregularities. *Dermoid cyst* - Also known as a **mature cystic teratoma**, it is a benign germ cell tumor that rarely causes hormonal disturbances. - While it can present with pelvic pain or a mass, it generally does not directly cause **menorrhagia**. *Epithelial ovarian cancer* - These are the most common type of ovarian cancer, but they typically present with non-specific symptoms such as **abdominal bloating**, **pelvic pain**, or changes in bowel habits. - They are not usually associated with **estrogen production** leading to **menorrhagia**. *Yolk sac tumour* - This is a rare, malignant germ cell tumour that is typically seen in young women and produces **alpha-fetoprotein (AFP)**. - It does not produce hormones that directly cause **menorrhagia** but can lead to rapid tumor growth and abdominal symptoms.

Q: Which of the following conditions can lead to elevated CA-125 levels?

All of the options. ***All of the options*** - **CA-125** is a tumor marker primarily associated with **ovarian cancer**, but it is **not specific** and can be elevated in various benign and malignant conditions. - All three conditions listed—**abdominal tuberculosis**, **cervical cancer**, and **endometriosis**—can cause elevated CA-125 levels, making this marker useful for monitoring but not diagnostic of a specific condition. **Abdominal tuberculosis:** - Causes peritoneal inflammation and ascites, leading to significant **CA-125 elevation** - Can mimic ovarian cancer clinically, making differentiation challenging - CA-125 levels may be markedly elevated (often >500 U/mL) **Cervical cancer:** - Particularly in **advanced stages** with peritoneal involvement, can elevate CA-125 - Elevation occurs due to adjacent tissue involvement and inflammatory response - Less commonly associated with CA-125 than ovarian pathology, but well-documented **Endometriosis:** - One of the most **common benign causes** of elevated CA-125 - Ectopic endometrial tissue and associated inflammation trigger CA-125 production - Levels typically moderate (35-200 U/mL) but can be higher with extensive disease

Q: What is the primary function of CA-125 in clinical practice?

CA-125: A glycoprotein, tumor marker for ovarian cancer. ***CA-125: A glycoprotein, tumor marker for ovarian cancer*** - **CA-125** is a **glycoprotein** that serves as a **tumor marker**, primarily recognized for its association with **ovarian cancer**. - While not exclusively specific to ovarian cancer, elevated levels are frequently observed in women with this malignancy, making it useful in diagnosis and monitoring [1]. *CA-125: Tumor marker specific only for ovarian cancer* - **CA-125** is **not specific only for ovarian cancer**; its levels can be elevated in various benign conditions [3]. - Conditions such as **endometriosis**, **pelvic inflammatory disease**, **uterine fibroids**, and even menstruation can cause elevated CA-125 levels. *CA-125: Diagnostic marker that confirms ovarian cancer diagnosis* - **CA-125** is **not a diagnostic marker that confirms ovarian cancer**; a definitive diagnosis requires a biopsy and histopathological examination [1]. - Its utility lies in aiding the **diagnosis**, monitoring **treatment response**, and detecting **recurrence**, but it cannot confirm the disease on its own [2]. *CA-125: Used primarily for screening healthy women for ovarian cancer* - **CA-125** is **not recommended for screening healthy women** due to its low specificity and sensitivity [1]. - Using CA-125 for general population screening would lead to a high rate of **false positives**, resulting in unnecessary invasive procedures.

Q: What does LEEP stand for in the management of cervical lesions?

Loop electrosurgical excision procedure. ***Loop electrosurgical excision procedure*** - **LEEP** is an acronym for **loop electrosurgical excision procedure**, a common method used to remove abnormal cells from the cervix - This procedure plays a crucial role in treating **high-grade cervical dysplasia** (CIN 2-3) and early-stage cervical cancer - It is both **diagnostic** (provides tissue for histopathology) and **therapeutic** (removes abnormal tissue) - The procedure uses a thin wire loop heated by electrical current to excise abnormal cervical tissue *Loop electromagnetic excision procedure* - Incorrect terminology; the "E" in **LEEP** stands for **electrosurgical**, not electromagnetic - Electromagnetic procedures are not standard for cervical lesion management *Loop electrodiagnostic excision procedure* - Incorrect terminology; while LEEP does provide diagnostic tissue, the "E" stands for **electrosurgical**, which describes the cutting technique - The term "electrodiagnostic" is not used in this context *Loop electrochemical excision procedure* - Incorrect terminology; the procedure uses **electrical current** for cutting and coagulation, not electrochemical reactions - The "E" in LEEP specifically refers to **electrosurgical** technique

Question 1

What condition is the EMACO regimen primarily used to treat?

Accepted Answer

Choriocarcinoma

Answer

Cervical cancer

Answer

Endometrial cancer

Answer

Ovarian cancer

Question 2

What is the recommended treatment for stage III B cervical cancer?

Accepted Answer

Combined chemoradiation (chemotherapy + radiotherapy)

Answer

Radical hysterectomy (Wertheim's operation)

Answer

Radiotherapy (external beam)

Answer

Chemotherapy (intravenous)

Question 3

What is the recommended approach for adjuvant treatment in endometrial carcinoma stage IA, grade I?

Accepted Answer

No adjuvant treatment

Answer

Radiotherapy

Answer

Chemotherapy

Answer

Chemotherapy plus radiotherapy

Question 4

In a patient with choriocarcinoma and jaundice, what is the most appropriate treatment option?

Accepted Answer

Multi-agent combination chemotherapy

Answer

Suction evacuation

Answer

Actinomycin D

Answer

Methotrexate

Question 5

In which of the following conditions is therapeutic conization MOST specifically indicated as the standard treatment approach?

Accepted Answer

Microinvasive carcinoma of the cervix

Answer

Severe Cervical Intraepithelial Neoplasia (CIN III) requiring excision

Answer

Benign cervical metaplasia

Answer

High-grade cervical dysplasia with unsatisfactory colposcopy

Question 6

Which of the following is the least likely site for metastasis in cases of vulvar cancer?

Accepted Answer

Paraaortic nodes

Answer

Urethra

Answer

Deep inguinal nodes

Answer

Superficial inguinal nodes

Question 7

Which ovarian tumour can present with menorrhagia ?

Accepted Answer

Granulosa cell tumour

Answer

Dermoid cyst

Answer

Epithelial ovarian cancer

Answer

Yolk sac tumour

Question 8

Which of the following conditions can lead to elevated CA-125 levels?

Accepted Answer

All of the options

Answer

Abdominal tuberculosis

Answer

Cervical cancer

Answer

Endometriosis

Question 9

What is the primary function of CA-125 in clinical practice?

Accepted Answer

CA-125: A glycoprotein, tumor marker for ovarian cancer

Answer

CA-125: Tumor marker specific only for ovarian cancer

Answer

CA-125: Diagnostic marker that confirms ovarian cancer diagnosis

Answer

CA-125: Used primarily for screening healthy women for ovarian cancer

Question 10

What does LEEP stand for in the management of cervical lesions?

Accepted Answer

Loop electrosurgical excision procedure

Answer

Loop electromagnetic excision procedure

Answer

Loop electrodiagnostic excision procedure

Answer

Loop electrochemical excision procedure

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?